Takuya Yagi

First‐in‐Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742, a Dual Antagonist of Toll‐like Receptors 7 and 8, in Healthy Volunteers

J. Aluri, S. Hojo, Y. Kitahara, 2022, Clinical pharmacology in drug development.

A novel Toll-like receptor 7/8-specific antagonist E6742 Ameliorates clinically relevant disease parameters in murine models of lupus.

S. Ishizaka, Qian Chen, Toshiyuki Shimizu, 2023, European journal of pharmacology.